Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420306 | 1.00 | KLK7 (0.47) | KLK7FKBP1ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL842288 | 0.91 | KLK7 (0.49) | KLK7FKBP1APARP1F2HPGD | |
| SCHEMBL12890921 | 0.91 | KLK7 (0.49) | KLK7FKBP1APARP1F2HPGD | |
| SCHEMBL1300740 | 0.91 | KLK7 (0.49) | KLK7FKBP1APARP1F2HPGD | |
| SCHEMBL20886535 | 0.87 | KMT2A (0.49) | KLK7FKBP1ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL19313922 | 0.87 | KMT2A (0.49) | KLK7FKBP1ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29816738 | 0.87 | KMT2A (0.49) | KLK7FKBP1ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL14664150 | 0.86 | SMN1; SMN2 (0.48) | FKBP1ASMN1; SMN2NPC1RAB9AHTR2C | |
| SCHEMBL28387613 | 0.86 | ELANE (0.48) | KLK7FKBP1ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20329117 | 0.86 | ELANE (0.48) | KLK7FKBP1ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| EP-3668837-B1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPHARMA LTD (KY) | 2022-07-06 | — | — | EP | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2021-02-18 | — | — | US | disclosed |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XW LABORATORIES INC. (KY) | 2020-12-08 | — | — | US | disclosed |
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2020-06-11 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150239840-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9035062-B2 | Process for preparing a compound useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | Meiji Seika Pharma. Co., Ltd. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8772490-B2 | Optically active diazabicyclooctane derivatives and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2657234-A1 | OPTICALLY-ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR MANUFACTURING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | KLK7 4463/4885FKBP1A 2462/4885SMN1; SMN2 702/4885 |
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | AIFM2, GPX1, GPX4 | KLK7 4677/4885FKBP1A 737/4885SMN1; SMN2 2497/4885 |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | AIFM2, GPX1, GPX4 | KLK7 4677/4885FKBP1A 737/4885SMN1; SMN2 2497/4885 |
| US-20120165533-A1 | OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | DCXR, CBR1, DECR1 | KLK7 4798/4885FKBP1A 4045/4885SMN1; SMN2 4302/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | KLK7 4783/4885FKBP1A 2852/4885SMN1; SMN2 2245/4885 |
| US-20140303375-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | TBC1D15, TBC1D5, TERT | KLK7 3457/4885FKBP1A 4853/4885SMN1; SMN2 2735/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | KLK7 4730/4885FKBP1A 3178/4885SMN1; SMN2 2493/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | KLK7 4463/4885FKBP1A 2462/4885SMN1; SMN2 702/4885 |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | KLK7 4677/4885FKBP1A 737/4885SMN1; SMN2 2497/4885 |
| US-20150239840-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | TERT, TBC1D5, TBC1D15 | KLK7 3171/4885FKBP1A 4553/4885SMN1; SMN2 3078/4885 |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | KLK7 4677/4885FKBP1A 737/4885SMN1; SMN2 2497/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | KLK7 4463/4885FKBP1A 2462/4885SMN1; SMN2 702/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | KLK7 4463/4885FKBP1A 2462/4885SMN1; SMN2 702/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | KLK7 4463/4885FKBP1A 2462/4885SMN1; SMN2 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.